Status: Recruiting
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
Participants needed: 81
Trial details
Phase: Phase 2Age: 8+Biological sex: AllType: InterventionalSponsor: Laboratoires TheaUpdated: Jun 18, 2026Locations: 28
Eligibility criteria
An adult (≥18 years) willing and able to provide informed consent for participat... [+8]
Presence of additional non-exon 13 USH2A pathogenic or likely pathogenic variant... [+7]